Company Encyclopedia
View More
name
Aesthetic Medicine
CP20072.HK
News
View More

Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%

Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%

marketscreener·
HK
02196
+2.23%
SH
600196
+2.21%
marketscreener·
HK
02196
+2.23%
SH
600196
+2.21%

Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio

Dec 18 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd (600196.SS) :* SAYS UNIT SIGNS DEAL WITH CLAVIS BIO FOR CO-DEVELOPMENT AND EXCLUSIVE LICENSING OPTIONS* SAYS COULD RECEIVE UP TO $362.5 MILLION PER PROJECT IF CLAVIS BIO EXERCISES OPTIONSource text Further company coverage: (600196.SS)

Reuters·
HK
02196
+2.23%
SH
600196
+2.21%
Reuters·
HK
02196
+2.23%
SH
600196
+2.21%

Pfizer, which has fallen behind in the GLP-1 race, is eyeing FOSUN PHARMA's oral medication

Pfizer has fallen behind in the GLP-1 race and is supplementing its shortcomings through a licensing collaboration with FOSUN PHARMA. FOSUN PHARMA has granted Pfizer global exclusive rights to the oral small molecule GLP-1 receptor agonist YP05002, with a potential total transaction amount of approximately $2.085 billion. YP05002 is still undergoing Phase I clinical trials in Australia and is an early-stage product. FOSUN PHARMA's innovative drug business revenue grew by 18.09%, becoming the company's growth engine

BambooWorks·
US
PFE
0.00%
SH
600196
+2.21%
HK
02196
+2.23%
BambooWorks·
US
PFE
0.00%
SH
600196
+2.21%
HK
02196
+2.23%

Morning Trend | CMS steadily rebounds, can the pharmaceutical sector open a rebound window?

CMS (867.HK) performed outstandingly on the 16th, with funds actively lifting the stock price in the early market, and the bullish atmosphere continued until the close. The stock price closed higher on the daily line, with recent trading volume expanding positively, and a local rebound chain emerging within the pharmaceutical sector. There are signs of tentative capital returning in batches, with increased follow-up buying. On the news front, the company's third-quarter earnings guidance continues to release positive signals. The commercialization progress of new drugs is smooth, leading to some capital spilling over into pharmaceutical growth stocks. Innovative drugs are under regulatory scrutiny, and the sector has recently received marginal policy benefits. The daily line has seen continuous volume expansion, and trading has become significantly active after breaking through the consolidation platform, with both 8-hour and 24-hour trends continuing to rise. The technical RSI indicator shows a short-term bias towards strength, and there may be fluctuations and repeated demand during the trading session. Overall, the pharmaceutical sector is still in a bottoming phase, and if the main capital continues to increase its control and volume, the rebound window is expected to open fully. In the short term, one should still guard against the pressure of a pullback after a rise and pay attention to whether the market can continue to attract incremental capital. The expansion of the market needs to rely on sustained volume and policy follow-up. Investors should focus on changes in capital inflow and flexibly grasp the rhythm of the rebound and volatility risks

Technical Forecast·
HK
00867
-0.60%
Technical Forecast·
HK
00867
-0.60%

Fosun Pharma Drops on Plan to Take Over Alzheimer's Drugmaker Green Valley for USD198.8 Million

Fosun Pharma plans to invest USD198.8 million to acquire a 51% stake in Green Valley Shanghai Pharmaceuticals, known for its Alzheimer's drug GV-971. Shares fell after the announcement. Fosun aims to enhance its central nervous system treatment portfolio and support clinical trials for GV-971. Green Valley faced production halts due to regulatory issues, posting a net loss of USD9.6 million. The acquisition is seen as a strategic move to improve Fosun's market position in CNS treatments.

Yicai·
HK
02196
+2.23%
SH
600196
+2.21%
Yicai·
HK
02196
+2.23%
SH
600196
+2.21%
Posts
View More

$Amazon(AMZN.US) will likely announce between 12 AM and 2:30 AM tonight,

the new Nova AI model + in-house Trainium 3 chip

Given Alibaba and Google's stock rose after announcing new models, mindlessly go...

$Nova Lifestyle(NVFY.US)💎 NVFY (Nova Lifestyle) — Order Book Snapshot 💎

📈 Latest Price: $5.42

📊 Buy Orders: 300.8K shares

📊 Sell Orders: 30.7K shares

🔥 Buy-side pressure dominates with a 10:1 ratio ...

  • 0
© 2025 Longbridge｜Disclaimer